Effects of adenovirus-mediated VEGF-siRNA on the growth of xenografted human osteosarcoma in nude mice

Tumor

Volumn 27, Issue 12, 2007, Pages 948-952

  Qian, Guang ^a   Mei, Jiong ^b   Dong, You Hai ^a   Cai, Xuan Song ^b  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Gene therapy; Mice, nude; Osteosarcoma; RNA, small interfering; Vascular endothelial growth factors

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN BCL 2; SMALL INTERFERING RNA; TETRAZOLIUM; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SIZE; CELL ACTIVITY; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EUKARYOTE; EXPRESSION VECTOR; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

EID: 77953471035     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. HOLZER G, OBERMAIR A, KOSCHAT M, et al. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors[J]. Med Pediatr Oncol,2001,36(6): 601-604.
2. FOLKMAN J. Anti-angiogenesis: new concept for therapy of solid tumors[J]. Ann Surg,1972,175(3):409-416.
3. ROSEN L S. VEGF-targeted therapy: therapeutic potential and recent advances[J]. Oncologist, 2005,10(6):382-391.
4. SENN C, HANGARTNER C, MOES S, et al. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides[J]. Eur J Pharmacol,2005,522(1):30-37.
5. KWON HS, SHIN H C, KIM J S. Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels[J]. Nucleic Acids Res, 2005,33(8):1-10.
6. ZHANG L, YANG N, MOHAMED-HADLEY A, et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer[J]. Biochem Biophys Res Commun,2003,303(4):1169-1178.
7. FERRER F A, MILLER L J, LINDQUIST R, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer[J]. Urology,1999,54(3):567-572.
8. LANGER I, VERTONGEN P, PERRET J, et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas [J]. Med Pediatr Oncol, 2003,34(6):386-393.
9. WU W, SHU X, HOVSEPYAN H, et al. VEGF receptor expression and signaling in human bladder tumors [J]. Oncogene,2003,22 (22):3361-3370.
10. LIU B, EARL H M, BABAN D, et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF [J]. Biochem Biophys Res Commun,1995,217(3):721-727.
11. MASOOD R, CAI J, ZHENG T, et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma [J]. Proc Natl Acad Sci USA, 1997,94(3):979-984.
12. HLATKY L, HAHNFELDT P, FOLKMAN J, et al. Clinical application of angiogenic therapy: microvessel density, what it does and doesn't tell us [J]. J Natl Cancer Inst,2002,94(12):883-893.
13. STREIT M, RICCARDI I, VELASCO P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis [J]. Proc Natl Acad Sci USA,1999,96(26):14888-14893.
14. PIDGON G, BARR M, HARMEY J H, et al. Vascular endothelial growth factor (VEGF) upregulate> Bcl-2 protein and inhibits apoptosis in human and murine mammol/Lary adenocarcinoma cell [J]. Br J Cancer,2001,85(2):273-278.
15. PAWAN K,APRIL I,PETER J,et al. p38 MAPK mediates γ-Irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway [J]. J Biol Chem, 2004, 279 (41): 43352-43360.
16. FERNANDEZ A, UDAGAWA T, SCHWESINGER C, et al. Angiogenic potential of prostate carcinoma cells overexpressing Bcl-2 [J]. J Natl Cancer Inst,2001,93(3):33-38.